Resistant hypertension in Nondialysis Chronic Kidney Disease

Silvio Borrelli, Luca De Nicola, Giovanna Stanzione, Giuseppe Conte, and Roberto Minutolo

Division of Nephrology, Second University of Naples, 80125 Naples, Italy

Correspondence should be addressed to Roberto Minutolo; roberto.minutolo@unina2.it

Received 24 January 2013; Accepted 26 March 2013

Academic Editor: Marina Politi Okoshi

Copyright © 2013 Silvio Borrelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Resistant hypertension (RH) is defined as blood pressure (BP) that remains above the target of less than 140/90 mmHg for general population and 130/80 mmHg in people with diabetes mellitus or chronic kidney disease (CKD) in spite of the use of at least three full-dose antihypertensive drugs including a diuretic or as BP that reaches the target by means of four or more drugs. In CKD, RH is a common condition due to a combination of factors including sodium retention, increased activity of the renin-angiotensin system, and enhanced activity of the sympathetic nervous system. Before defining the hypertensive patient as resistant it is mandatory to exclude the so-called “pseudoresistance.” This condition, which refers to the apparent failure to reach BP target in spite of an appropriate antihypertensive treatment, is mainly caused by white coat hypertension that is prevalent (30%) in CKD patients. Recently we have demonstrated that “true” RH represents an independent risk factor for renal and cardiovascular outcomes in CKD patients.

1. Definition and Prevalence of Resistant Hypertension in General Population

Hypertension is defined “resistant” (RH) when blood pressure (BP) levels persist above the therapeutic target (<140/90 mmHg for general population and <130/80 mmHg for patients with diabetes mellitus or chronic kidney disease (CKD)), despite the use of at least three antihypertensive drugs at full dose, including the diuretic. Furthermore, according to the current definition, also hypertensive patients who reach BP target by means of four or more drugs are considered resistant [1, 2].

Although the exact prevalence is unknown, several observational studies suggest that RH is a common clinical problem in general population [3–8]. In a recent analysis of NHANES 2003–2008, about 9% of 5,230 hypertensive patients can be identified as resistant to treatment. This prevalence increased to 13% when only treated patients were considered [3].

Main causes of RH are reported in Table I. RH may be caused by biological-behavioral factors (such as smoking and obesity), drugs (NSAOIDs, steroids, and cyclosporine) or exogenous substances (liquorice, ginseng, etc.), and secondary causes of hypertension. Among these, CKD is most relevant for its epidemiological impact [8]. Indeed, the prevalence of CKD is rapidly rising worldwide with approximately 10% of the adult population currently affected [9]. Notably, 65–95% of CKD patients develop hypertension, as the glomerular filtration rate (GFR) declines from 85 to 15 mL/min [10], and hypertension is a determinant of progression of renal damage, especially in proteinuric and diabetic patients [11, 12], and of cardiovascular risk [13].

2. Pseudoresistance

Before defining the hypertensive patient as resistant it is mandatory to exclude the so-called “pseudoresistance.” This condition refers to the “apparent” failure to reach BP target, in spite of an appropriate antihypertensive treatment. Among the causes of pseudoresistance (Table 2), the most frequent is represented by the presence of white coat hypertension (WCH). Ambulatory blood pressure monitoring (ABPM) or home blood pressure (HBP) allows the identification of white coat effect defined by the coexistence of persistently high.
Table 1: Determinants of resistant hypertension in general population.

| Clinical condition          |
|-----------------------------|
| Diabetes mellitus           |
| Older age                   |
| Obesity                     |
| Drugs                       |
| Nonsteroidal anti-inflammatory drugs |
| Corticosteroids             |
| Oral contraceptive hormones |
| Erythropoietin              |
| Cyclosporine and tacrolimus |
| Sympathomimetics (decongestants) |
| Exogenous substances        |
| Tobacco                     |
| Alcohol                     |
| Cocaine, amphetamines, and other illicit drugs |
| Licorice                    |
| Herbal supplements (ginseng, yohimbine) |
| Secondary causes            |
| Common                      |
| Chronic Kidney disease      |
| Primary aldosteronism       |
| Sleep apnea                 |
| Hyper-hypothyroidism        |
| Renal artery disease        |
| Uncommon                    |
| Cushing's syndrome          |
| Pheochromocytoma            |
| Aortic coarctation          |
| Hyperparathyroidism         |

Office BP with normal ABP or HBP. Therefore, out-of-office monitoring of BP is the essential tool for correctly diagnosing RH. Indeed, in the Spanish ABP registry, 12% of the 68,045 patients examined were diagnosed as RH; however, after ABP monitoring, as many as 37% of them were identified as pseudoresistant [14].

The second critical aspect for excluding pseudoresistance is the assessment of adherence to antihypertensive therapy. Lack of adherence is frequently encountered in clinical practice; indeed, nearly half of patients with hypertension withdraw therapy within the first year after diagnosis [15], and that, over 10 years of follow-up, about 40% of patients discontinue permanently antihypertensive drugs [15, 16]. The main causes of poor compliance are represented mainly by the fear of side effects, complicated treatment plans, poor doctor-patient communication, and costs of therapy (Table 2).

3. Resistant Hypertension in CKD Patients

CKD is at the same time cause and complication of poorly controlled hypertension. The evaluation of RH in CKD patients is highly relevant for two main reasons. First, RH is common in CKD patients, and its prevalence increases with worsening of kidney damage (Figure 1) [17]. Second, RH represents an independent risk factor for renal, and cardiovascular (CV) outcomes in CKD patients [17, 18].

Several surveys in CKD patients have demonstrated a high incidence of uncontrolled hypertension in clinical practice. Indeed the BP target is reached in only a small proportion (10–20%), both in nephrology and nonnephrology settings [19–24].

However, uncontrolled hypertension is not equivalent of RH. This is particularly true in CKD patients in whom WCH is a common feature. Indeed, we have previously reported that WCH occurred in about 30% of patient with office BP ≥ 130/80 mmHg [25], and, as illustrated in Figure 2, its prevalence increased with aging [26]. More recently, our group has confirmed this finding in a larger cohort of CKD patients evidencing that pseudoresistance involved 24% of patients [17], defined as resistant only on the basis of office BP and drug number [1]. Of note, prevalence of pseudoresistance is typically encountered in early stages of CKD and virtually disappeared in CKD stage 5 (Figure 1) [17].

Contemporary assessment of ABP monitoring, therefore, allowed to disclose a prevalence of “true” RH of 23–25% in CKD patients [17, 18], that corresponds to a prevalence three times greater than that reported in essential hypertension (~8%) [14]. In addition, when nephrologists intensify antihypertensive therapy to reach BP target, the prevalence of RH increases from 26% to 38%. Our retrospective study also evidenced that diabetes and proteinuria are main determinants of RH [18].

4. Pathogenesis of RH in CKD Patients

The pathogenesis of hypertension in CKD is multifactorial being a combination of factors including sodium retention, increased activity of the renin-angiotensin system, and enhanced activity of the sympathetic nervous system; this may in part justify the low success rate of antihypertensive treatment [27]. The most frequent pathophysiological disorder is the salt and water retention occurring in the majority of patients with reduced glomerular filtration rate (GFR). The resulting expansion of the ECV allows preserving the external balance of sodium, but with consequent development of persistent and often refractory hypertension therapy. In these patients, the entity of ECV expansion is directly dependent on the degree of GFR impairment and corresponds to approximately 5% to 10% of body weight, even in the absence of peripheral edema [28]. Of note, the salt sensitivity of BP is not a feature limited to the advanced stages of renal disease, but begins before the development of clear hypertension and severe GFR decline [29, 30]. The fact that sodium excretion is commonly impaired in CKD is further testified by the large prevalence of nocturnal hypertension in CKD as compared to essential hypertension [31–33]. Furthermore, in CKD
patients, systemic hypertension is sustained by the activation of renin-angiotensin system (RAS), which is inappropriate compared to expansion of the ECV. The ensuing glomerular hyperfiltration leads to the progressive kidney damage in the long term. The institution of measures to help prevent this process, such as antihypertensive therapy with an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, may slow progressive disease and even preserve renal function [34]. It is of interest that in our prospective study [17], we found that mean urinary excretion of sodium was higher in RH patients ($P = 0.004$), and consequently the adherence to low-salt diet was poorer ($P = 0.026$) (Figure 3).

Therapeutic interventions aimed to inhibit the SRA and to reduce the ECV expansion frequently are insufficient at normalizing hypertension status in these patients, suggesting additional mechanisms in the pathophysiology of CKD-related hypertension. A series of experimental observations has allowed, in fact, generating new hypotheses such as the increase adrenergic activity, secondary hyperparathyroidism, and dysregulation of endothelial factors regulating the contractility of smooth muscle vessel [27]. Finally, some lines of evidence have recently indicated that sleep disturbances prevalence is higher in subjects with CKD. Given that sleep apnea might be a cause of RH (Table 1), it might contribute to explain the high prevalence of RH in subjects with CKD [35].

5. Prognosis of RH in CKD

In the population with essential hypertension, a relationship between RH and cardiovascular risk has been reported [36, 37]. Furthermore, studies have shown that presence of mild-to-moderate GFR reduction and/or microalbuminuria amplifies the cardiovascular risk correlated to RH in the general hypertensive population [38, 39]. However, only two studies evaluated the prognostic role of RH in patients with established CKD and more advanced renal damage [17, 18]. In a retrospective study, we evidenced that RH was associated with greater risk of renal death (HR 1.85, 95% CI, 1.13–3.03), independently from main clinical features and degree of BP control [18]. This finding has been confirmed by our group in a very recent prospective study in a cohort of 436 hypertensive CKD patients under nephrology care [17]. In that study, we assessed the risk of ESRD and fatal and nonfatal CV events in CKD patients stratified by presence of hypertension with and without RH. During 52.0 months of follow-up, 165 renal events and 109 fatal and non-fatal CV events were documented. Patients with normal ABP had the best prognosis for either outcome independent of their RH status, whereas the highest risk for cardio-renal events was observed only in true resistance. Indeed, in comparison with sustained hypertension, true resistance predicted CV risk (HR 2.05, 95% CI, 1.23–3.43) but not renal risk (HR 1.23, 95% CI, 0.83–1.82).

Of note, in pseudoresistant patients, ABP profiles, target organ damage (prevalence of LVH and severity of renal disease) did not differ from normotensive patients, and their cardio-renal outcome was comparable to that of control patients [17]. This result is clinically relevant and supports the need to identify pseudoresistant CKD patients to avoid aggressive antihypertensive therapy. Indeed, these patients were characterized by systolic BP levels during daytime, and especially at nighttime, close to the threshold limit of hypoperfusion (100 mmHg). Under these circumstances, a tighter control of BP merely based on the detection of elevated BP in office may expose patients to ischemia-induced

---

**Table 2: Causes of pseudoresistance.**

| Cause                                      |
|--------------------------------------------|
| White coat effect                         |
| Adherence therapy                         |
| Side effect of medication                 |
| Complicated dosing schedules              |
| Poor relation between doctor and patients |
| Costs of medication                       |
| Improper blood pressure measurement       |
| Incorrect cuff size                       |
| Related to antihypertensive medication     |
| Inadequate doses of diuretic              |
| Inappropriate combination                 |

---

**Figure 1:** Prevalence of true resistance (black bar) and pseudoresistance (gray bar) in CKD stages [17].

**Figure 2:** Prevalence of white coat hypertension in CKD patients stratified by age [26]. $P = 0.001$ for trend.
worsening of cardio-renal damage [40, 41] and eventually convert their prognosis from favourable to unfavourable.

The mechanisms underlying the different prognostic value of RH are not readily apparent; however, we can hypothesize that persistence of hypertension despite optimal antihypertensive treatment specifically identifies patients with more severe vascular damage. Diabetes, left ventricular hypertrophy, higher proteinuria, and, as mentioned, high salt intake, variables that we found independently associated with true resistance, are in fact all associated with endothelial dysfunction and arterial stiffness [42–45]. In particular, CKD has shown that proteinuria, rather than GFR, relates to the severity of hypertension [46]. Indeed, although low GFR is recognized as a CV risk factor [47], proteinuria in CKD patients is considered a better marker of the presence of vascular disease [48, 49].

6. Possible Therapeutic Interventions in RH Patients with CKD

The multifactorial pathogenesis of hypertension in CKD imposes a multilevel treatment in these patients, even though to date there are no studies that assessed whether a particular combination of antihypertensive drugs is most advantageous to control hypertension in RH patients. The AASK study suggested that use of dihydropyridinic calcium-channel blocker (amlodipine) might not be adequate for use in CKD subjects, possibly because of increasing the GFR and thus inducing glomerular damage [50]. More recently, REIN-2 study has shown that felodipine (dihydropyridinic calcium-channel blocker) added to a background therapy with CEI may be safely used in CKD individuals for reaching low BP target, but it did not reduce the progression to ESRD [51]. Finally, a recent systematic review suggested that the treatment with beta-blockers improved all-cause mortality in patients with CKD and heart failure [52], but these drugs did not appear having a renoprotective effect [50].

In CKD patients with RH, the pivotal intervention is certainly represented by the restriction of sodium intake. This dietary measure, however, is scarcely implemented as testified by the poor adherence (~20%) to low sodium diet even in patients regularly followed in nephrology clinics [53]. This is a paradoxical condition if one considers the high salt sensitivity of CKD as well as the positive results obtained in the few pilot studies published to date. Koomans et al. found that lower sodium intake markedly diminished BP in patients with advanced CKD [54]. Interestingly, we suggested that salt restriction may contribute to the improvement in renal outcome observed in CKD patients treated with or without dietary protein restriction [29, 55]. Finally, it also is well recognized that a reduction in daily sodium intake enhances the antihypertensive and antiproteinuric effects of converting enzyme inhibitors [56]. More importantly, a small randomized cross-over trial of dietary salt restriction in RH patients has demonstrated that low-salt diet significantly decreased office systolic and diastolic BP (by 23 and 9 mmHg, resp.) and 24-h BP from 150/82 to 130/72 mmHg [57].

The critical role of salt retention in CKD-dependent hypertension precludes optimal control of BP during pharmacological treatment with antihypertensive agents, especially vasodilators [28] that are prescribed in almost half of CKD patients [53]. Indeed, early studies have shown that, to obtain full expression of the antihypertensive effects of minoxidil, a potent vasodilating agent, it is necessary to antagonize its antinatriuretic side effects by coadministering a diuretic agent or limiting the vasodilation-induced activation
of the renin-angiotensin and adrenergic nervous systems [58, 59].

Improving compliance to a low-salt diet in hypertensive patients with CKD is helpful to make patient aware of the importance of low-salt intake to prevent progression of CV disease and CKD, to instruct patient on the correct way to collect 24-hour urine specimen, to monitor 24-hour urinary sodium excretion at each visit (target, 100 mmol/day), to communicate to patient the daily salt intake estimated by 24-hour urinary sodium excretion (target, 6 g/day), and to give specific recommendations on sodium restriction in diet listed in the following list.

Ten recommendations to restrict sodium in your diet:

1. move the salt shaker away from the table;
2. cook pasta, rice, and cereals without salt (add in smaller amount directly on cooked food);
3. in cooking and at the table, increase the use of spices (e.g., herbs, lemon, vinegar, and hot pepper);
4. abolish salt-containing condiments (e.g., ketchup, mayonnaise, mustard, and barbecue sauce);
5. look for the amount of sodium on food labels;
6. look for low-salt bread and fresh or plain frozen foods;
7. cut down frozen dinners, canned soups, packaged mixes, cured meat and fish (e.g., ham, bacon, anchovies, and salmon);
8. choose fresh rather than seasoned cheese;
9. rinse canned foods (e.g., tuna) to remove some sodium;
10. abolish salty snack foods (e.g., chips, nuts).

Generally diuretics are included in the definition of RH; however, in CKD patients the most crucial task of diuretic therapy is to properly select class and dose in relation to the level of kidney function. Indeed, if patients with mild renal impairment (GFR > 40 mL/min/1.73 m²) may respond to thiazide diuretics, those with more advanced CKD require the use of more potent loop diuretics administered at doses proportional to the reduced GFR [60]. In a clinical trial performed in patients with GFR in the range 10–40 mL/min, correction of volume expansion, as evidenced by a decrement in body weight of approximately 2.0 kg and a parallel marked reduction in BP, was safely induced by oral administration of only furosemide at doses inversely proportional to GFR level (1.0, 2.5, and 4.0 mg/kg body weight per day in patients with GFRs of 40–31, 30–20, and 19–10 mL/min, resp.) [61]. Therefore to improve the modalities of diuretic treatment is helpful to begin with a low dose and gradually increase the dose to obtain progressive reduction of the body weight (0.5–1 kg/day) until to correction of sodium retention. Alternatively, the diuretic resistance can be overcome with the addition of thiazides, such as metolazone, that blocks the reabsorption of sodium in the distal segments, thereby reducing the breaking phenomenon [62]. Disappointingly enough, nephrologists are today still reluctant to adequately use loop diuretics in their hypertensive CKD patients. This erroneous attitude cannot be justified by the fear of side effects, which are infrequent, usually reversible and predictable when the patient is checked periodically [53, 63].

A further diuretic agent successfully tested in RH patients is spironolactone based on the finding that plasma aldosterone levels are higher in RH that in those with controlled hypertension [64]. Recently, ASPIRANT study, a randomized, controlled, double-blind study evaluated the antihypertensive effects of spironolactone in 117 patients with RH. Spironolactone was administered at doses of 25 mg/day for 8 weeks in addition to the preexisting therapy. At the end of 8 weeks of the study, systolic BP (both measured in the office and outpatient) was significantly reduced in treated patients in the absence of adverse effects [65]. However, despite their efficacy, antialdosterone drugs must be used very carefully in CKD with advanced disease (GFR < 30 mL/min/1.73 m²) due to the higher risk of hyperkalemia.

A novel therapeutic approach for RH is represented by catheter-based radiofrequency ablation of the renal sympathetic nerves, which was originally proposed in essential hypertension [1, 2]. More recently, one study assessed this intervention in moderate-to-severe CKD [66]. Fifteen patients with GFR < 45 mL/min/1.73 m² were successfully treated with renal ablation with a significant systolic/diastolic BP reduction being evident after 1 month from intervention (−34/−12 mmHg) and persisting at one year (−33/−19 mmHg) [66]. However, this is a small study with relatively short-term follow-up, and ultimate safety and efficacy of the catheter-based renal denervation procedure must await longer follow-up in a larger group of patients with CKD; indeed, of the five patients followed for 12 months, eGFR appears to have declined precipitously in one and more gradually in three others compared with the value at 6 months [66]. A trial in a larger group of patients is now underway prior to seeking approval from the Food and Drug Administration for approval of the radio catheter device. However, we are at the very beginning of the use of this invasive approach, and more data are needed before claiming for a therapeutic success. This holds true for carotid baroreceptor stimulator that has been tested in essential resistant hypertension [67] but not in CKD patients.

7. Conclusions

RH is a common condition in CKD due to a combination of factors including sodium retention, increased activity of the renin-angiotensin system, and enhanced activity of the sympathetic nervous system. However, the higher prevalence of WCH in these patients imposes an out-of-office monitoring (ABPM or HBP) to distinguish between pseudoresistance and true RH. Therefore a more large use of ABPM in CKD patients is ausplicable to attempt to limit the misclassification of hypertensive status in order to avoid unnecessary aggressive antihypertensive medication. To date the degree to which cardiovascular risk is reduced with treatment of resistant hypertension is unknown. Catheter-based radiofrequency ablation of the renal sympathetic nerves has been proposed, even though a greater implementation of a low-salt diet...
and a adequate use of the diuretic may be the first-choice therapeutic approach for controlling RH in CKD patients.

References

[1] D. A. Calhoun, D. Jones, S. Textor et al., “Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research,” Circulation, vol. 117, no. 25, pp. 510–526, 2008.

[2] P. A. Sarafidis and G. L. Bakris, “Resistant hypertension: an overview of evaluation and treatment,” Journal of the American College of Cardiology, vol. 52, no. 22, pp. 1749–1757, 2008.

[3] S. D. Persell, “Prevalence of resistant hypertension in the United States, 2003–2008,” Hypertension, vol. 57, no. 6, pp. 1076–1080, 2011.

[4] E. Pimenta and D. A. Calhoun, “Resistant hypertension: incidence, prevalence, and prognosis,” Circulation, vol. 125, no. 13, pp. 1594–1596, 2012.

[5] I. Hajjar and T. A. Kotchen, “Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000,” Journal of the American Medical Association, vol. 290, no. 2, pp. 199–206, 2003.

[6] C. D. Furbeger, J. T. Wright, B. R. Davis et al., “Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).” Journal of the American Medical Association, vol. 288, no. 23, pp. 2981–2997, 2002.

[7] P. A. Sarafidis, P. Georgianos, and G. L. Bakris, “Resistant hypertension: its identification and epidemiology,” Nature Reviews Nephrology, vol. 9, no. 1, pp. 51–58, 2012.

[8] M. Moser and J. F. Setaro, “Resistant or difficult-to-control hypertension,” The New England Journal of Medicine, vol. 355, no. 4, pp. 385–392, 2006.

[9] M. El Nahas, “The global challenge of chronic kidney disease,” Kidney International, vol. 68, no. 6, pp. 2918–2929, 2005.

[10] M. J. Klag, P. K. Whelton, B. L. Randall et al., “Blood pressure and end-stage renal disease in men,” The New England Journal of Medicine, vol. 334, no. 1, pp. 13–18, 1996.

[11] T. H. Jafar, P. C. Stark, C. H. Schmid et al., “Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis,” Annals of Internal Medicine, vol. 139, no. 4, pp. 244–253, 2003.

[12] M. J. Sarnak, T. Greene, X. Wang et al., “The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study,” Annals of Internal Medicine, vol. 142, no. 5, pp. 342–351, 2005.

[13] A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1307, 2004.

[14] A. De La Sierra, J. Segura, J. R. Banegas et al., “Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring,” Hypertension, vol. 57, no. 5, pp. 898–902, 2011.

[15] G. Mazzaglia, L. G. Mantovani, M. C. J. M. Stirkenboom et al., “Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care,” Journal of Hypertension, vol. 23, no. 11, pp. 2093–2100, 2005.

[16] B. L. G. Van Wijk, O. H. Klungel, E. R. Heerdink, and A. De Boer, “Rate and determinants of 10-year persistence with antihypertensive drugs,” Journal of Hypertension, vol. 23, no. 11, pp. 2101–2107, 2005.

[17] L. De Nicola, F. B. Gabbai, R. Agarwal et al., “Prevalence and prognostic role of resistant hypertension in Chronic Kidney Disease,” Journal of the American College of Cardiology. In press.

[18] L. De Nicola, S. Borrelli, F. B. Gabbai et al., “Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease,” Kidney and Blood Pressure Research, vol. 34, no. 1, pp. 58–67, 2011.

[19] L. De Nicola, P. Chiocini, C. Zoccali et al., “Prognosis of CKD patients receiving outpatient nephrology care in Italy,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2421–2428, 2011.

[20] R. Marin, F. Fernández-Vega, M. Gorostidi et al., “COPARENAL (Control de la Hipertensión Arterial en Pacientes con Insuficiencia RENAL) study investigators. Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study,” Journal of Hypertension, vol. 24, pp. 395–402, 2006.

[21] P. E. Stevens, D. J. O’Donoghue, S. De Lusignan et al., “Chronic kidney disease management in the United Kingdom: NEOERICA project results,” Kidney International, vol. 72, no. 1, pp. 92–99, 2007.

[22] R. Minutolo, L. De Nicola, P. Zamboli et al., “Management of hypertension in patients with CKD: differences between primary and tertiary care settings,” American Journal of Kidney Diseases, vol. 46, no. 1, pp. 18–25, 2005.

[23] R. Minutolo, F. C. Sasso, P. Chiocini et al., “Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings,” Journal of Hypertension, vol. 24, no. 8, pp. 1655–1661, 2006.

[24] L. De Nicola, S. Borrelli, P. Chiocini et al., “Hypertension management in chronic kidney disease: translating guidelines into daily practice,” Journal of Nephrology, vol. 24, no. 6, pp. 733–741, 2011.

[25] R. Minutolo, S. Borrelli, R. Scigliano et al., “Prevalence and clinical correlates of white coat hypertension in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2217–2223, 2007.

[26] R. Minutolo, S. Borrelli, P. Chiocini et al., “Effects of age on hypertensive status in patients with chronic kidney disease,” Journal of Hypertension, vol. 25, no. 11, pp. 2325–2333, 2007.

[27] V. M. Campese, N. Mitra, and D. Sandee, “Hypertension in renal parenchymal disease: why is it so resistant to treatment?” Kidney International, vol. 69, no. 6, pp. 967–973, 2006.

[28] L. De Nicola, R. Minutolo, V. Bellizzi et al., “Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease,” Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 306–313, 1996.

[29] Y. Konishi, N. Okada, M. Okamura et al., “Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin A nephropathy,” Hypertension, vol. 38, no. 1, pp. 81–85, 2001.
[31] R. Minutolo, R. Agarwal, S. Borrelli et al., “Prognostic role of ambulatory blood pressure measurement in patients with non-dialysis chronic kidney disease,” *Archives of Internal Medicine*, vol. 171, no. 12, pp. 1090–1098, 2011.

[32] R. Minutolo, F. B. Gabbai, S. Borrelli et al., “Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial,” *American Journal of Kidney Diseases*, vol. 50, no. 6, pp. 908–917, 2007.

[33] G. Remuzzi, N. Perico, M. Macia, and P. Ruggenenti, “The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease,” *Kidney International*, no. 99, pp. S57–S65, 2005.

[34] N. F. Turek, A. C. Ricardo, and J. P. Lash, “Sleep disturbances as nontraditional risk factors for development and progression of CKD: review of the evidence,” *American Journal of Kidney Diseases*, vol. 60, pp. 823–833, 2012.

[35] G. F. Salles, C. R. L. Cardoso, and E. S. Muxfeldt, “Prognostic influence of office and ambulatory blood pressures in resistant hypertension,” *Archives of Internal Medicine*, vol. 168, no. 21, pp. 2340–2346, 2008.

[36] S. L. Daugherty, J. D. Powers, D. J. Magid et al., “Incidence and prognosis of resistant hypertension in hypertensive patients,” *Circulation*, vol. 125, pp. 1635–1642, 2012.

[37] G. F. Salles, C. R. L. Cardoso, V. S. Pereira, R. Fiszman, and E. S. Muxfeldt, “Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: A Cohort Study,” *Journal of Hypertension*, vol. 29, pp. 2014–2023, 2011.

[38] G. F. Salles, C. R. L. Cardoso, R. Fiszman, and E. S. Muxfeldt, “Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension,” *Atherosclerosis*, vol. 216, no. 1, pp. 199–204, 2011.

[39] B. F. Palmer, “Renal dysfunction complicating the treatment of hypertension,” *The New England Journal of Medicine*, vol. 347, no. 16, pp. 1256–1261, 2002.

[40] J. B. Lewis, “Blood pressure control in chronic kidney disease: is less really more?” *Journal of the American Society of Nephrology*, vol. 21, no. 7, pp. 1086–1092, 2010.

[41] M. P. Kao, D. S. Ang, S. J. Gandy et al., “Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease,” *Journal of the American Society of Nephrology*, vol. 22, no. 7, pp. 1382–1389, 2011.

[42] A. I. Christen, R. L. Armentano, A. Miranda et al., “Arterial wall structure and dynamics in type 2 diabetes mellitus methodological aspects and pathophysiological findings,” *Current Diabetes Reviews*, vol. 6, no. 6, pp. 367–377, 2010.

[43] M. R. Weir, R. R. Townsend, J. C. Fink et al., “Hemodynamic correlates of proteinuria in chronic kidney disease,” *Clinical Journal of the American Society of Nephrology*, vol. 6, pp. 2403–2410, 2011.

[44] P. W. Sanders, “Vascular consequences of dietary salt intake,” *American Journal of Physiology*, vol. 297, no. 2, pp. F237–F243, 2009.

[45] M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention,” *Hypertension*, vol. 42, no. 5, pp. 1050–1065, 2003.

[46] R. Agarwal and R. P. Light, “GFR, proteinuria and circadian blood pressure,” *Nephrology Dialysis Transplantation*, vol. 24, no. 8, pp. 2400–2406, 2009.

[47] D. De Zeeuw, G. Remuzzi, H. H. Parving et al., “Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy,” *Circulation*, vol. 110, no. 8, pp. 921–927, 2004.

[48] B. R. Hemmelgarn, B. J. Manns, A. Lloyd et al., “Relation between kidney function, proteinuria, and adverse outcomes,” *Journal of the American Medical Association*, vol. 303, no. 5, pp. 423–429, 2010.

[49] J. T. Wright, G. Bakris, T. Greene et al., “Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial,” *Journal of the American Medical Association*, vol. 288, no. 19, pp. 2421–2431, 2002.

[50] P. Ruggenenti, A. Perna, G. Loriga et al., “Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial,” *The Lancet*, vol. 365, no. 9463, pp. 939–946, 2005.

[51] S. V. Badve, M. A. Roberts, C. M. Hawley et al., “Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis,” *Journal of the American College of Cardiology*, vol. 58, pp. 1152–1161, 2011.

[52] L. De Nicola, R. Minutolo, C. Gallo et al., “Management of hypertension in chronic kidney disease: The Italian multicentric study,” *Journal of Nephrology*, vol. 18, no. 4, pp. 397–404, 2005.

[53] H. A. Koomans, J. C. Roos, E. J. D. Mees, and I. M. K. Delawi, “Sodium balance in renal failure: a comparison of patients with normal subjects under extremes of sodium intake,” *Hypertension*, vol. 7, no. 5, pp. 714–721, 1985.

[54] V. Bellizzi, B. R. Di Iorio, L. De Nicola et al., “Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease,” *Kidney International*, vol. 71, no. 3, pp. 245–251, 2007.

[55] M. C. J. Slagman, F. Waanders, M. H. Hemmelder et al., “Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial,” *British Medical Journal*, vol. 343, no. 7818, 2011.

[56] E. Pimenta, K. K. Gaddam, S. Oparil et al., “Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial,” *Hypertension*, vol. 54, no. 3, pp. 475–481, 2009.

[57] W. A. Pettenger and H. Mitchell, “Renin release, saralasin and the vasodilator beta blocker drug interaction in man,” *The New England Journal of Medicine*, vol. 292, no. 23, pp. 1214–1217, 1975.

[58] S. L. Linas and A. S. Nies, “Minoxidil,” *Annals of Internal Medicine*, vol. 94, no. 1, pp. 61–65, 1981.

[59] B. D. Rose, “Diuretics,” *Kidney International*, vol. 39, no. 2, pp. 336–352, 1991.

[60] A. Dal Canton, G. Fuiano, G. Conte et al., “Mechanism of increased plasma urea after diuretic therapy in uraemic patients,” *Clinical Science*, vol. 68, no. 3, pp. 255–261, 1985.

[61] D. Fliser, M. Schröter, M. Neubeck, and E. Ritz, “Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure,” *Kidney International*, vol. 46, no. 2, pp. 482–488, 1994.

[62] M. Moser, “Why are physicians not prescribing diuretics more frequently in the management of hypertension?” *Journal of the American Medical Association*, vol. 279, no. 22, pp. 1815–1816, 1998.
[64] K. K. Gaddam, M. K. Nishizaka, M. N. Pratt-Ubunama et al., “Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion,” *Archives of Internal Medicine*, vol. 168, no. 11, pp. 1159–1164, 2008.

[65] J. Vaclavík, R. Sedlak, M. Plachy et al., “Addition of spironolactone in patients with resistant arterial hypertension (ASPI-RANT): a randomized, double-blind, placebo-controlled trial,” *Hypertension*, vol. 57, pp. 1069–1075, 2011.

[66] D. Hering, F. Mahfoud, A. S. Walton et al., “Renal denervation in moderate to severe CKD,” *Journal of the American Society of Nephrology*, vol. 23, pp. 1250–1257, 2012.

[67] K. Heusser, J. Tank, S. Engeli et al., “Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients,” *Hypertension*, vol. 55, no. 3, pp. 619–626, 2010.